| Document |
Document Title |
|
WO/1999/019558A2 |
The invention relates to the use of malonaldehyde derivatives of formula (I) for dyeing fibres containing keratin, in the presence of at least one compound with a primary or secondary amino group or hydroxy group chosen from primary or s...
|
|
WO/1999/014257A1 |
Monoesters and macrocyclic diesters of 2,2,4-trimethyl-1,3-pentanediol and phthalic acid or a derivative thereof are described. Methods by which such monoesters and diesters may be prepared are also described. The mono- and diesters acco...
|
|
WO/1999/012921A1 |
A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, and asthma which comprises administering to a mam...
|
|
WO/1999/005136A1 |
The present invention provides a compound of formula (I), wherein R?1¿ and R?2¿ are the same or different and are independently H, C¿1?-C¿6? straight-chain or branched-chain saturated or unsaturated alkyl, aryl, R?6¿CH¿...
|
|
WO/1999/000441A1 |
The invention concerns monomers with dilactonic cycle and the corresponding polymers, their preparation, and materials containing these polymers. The monomers are of formula (IIIa) in which R is the residue of a acid derived from an ose ...
|
|
WO/1998/047891A1 |
Cyclic products are prepared by selective olefin metathesis of bifunctional or polyfunctional substrates in the presence of one or several homogeneous or heterogeneous metathesis catalysts in a reaction medium. The invention is character...
|
|
WO/1998/027105A1 |
Probes labeled with 1,2-dioxetane precursors can be employed in a variety of assays. The probes may be nucleic acid, peptide nucleic acid, proteins including enzyme, antibody or antigen, steroid, carbohydrate, drug or non-drug hapten. Th...
|
|
WO/1998/025606A1 |
Novel derivatives of benzodioxole, benzofuran, 2,3-dihydrobenzofuran, and benzodioxane are useful as melatonergic agents.
|
|
WO/1998/019989A1 |
Stable, enzymatically triggered chemiluminescent 1,2-dioxetanes with improved water solubility and storage stability are provided as well as synthetic processes and intermediates used in their preparation. Dioxetanes further substituted ...
|
|
WO/1998/005607A2 |
The use of anorganic or organic polyacids to treat mineral fertilizers, in particular the use of polyacids as a mixture with at least one nitrification inhibitor to treat mineral fertilizers. The invention also concerns the use of select...
|
|
WO/1997/047611A1 |
Compounds of formula (I), wherein R1 and R2 are independently hydrogen, unsubstituted lower alkyl or lower alkyl substituted by lower alkoxy or lower alkyl thio, or acyl which is unsubstituted or substituted by one or more of lower alkyl...
|
|
WO/1997/036893A1 |
The invention relates to a group of new piperazine and piperidine compounds having interesting pharmacological properties. It has been found that compounds of formula (a) wherein A represents a heterocyclic group of 5-7 ring atoms wherei...
|
|
WO/1997/017322A1 |
Disclosed are "acid-amide" calixarenes of formula (I) wherein: L is [-CH2-] or [-O-CH2-O-] and may be the same or different between each aryl group; R5 is H, halogen, or C1-C10 aliphatic hydrocarbyl group, C6-C20 aryl group, C6-C20 hydro...
|
|
WO/1997/014692A1 |
A new class of stable dioxetanes bears a polycyclic stabilizing group and aryloxy moiety, the oxygen atom of which is provided with a protective group which can be removed by an enzymatic or chemical trigger admixed with the dioxetane. T...
|
|
WO/1997/014954A1 |
Dioxetanes that can be triggered by bases are provided which can be used to detect bases in organic solvents, aqueous preparations and detect gaseous bases in the atmosphere. The dioxetanes can be used to detect the release of bases from...
|
|
WO/1997/014696A2 |
The invention concerns compounds of general formulae (Ia) and (Ib), in which R1 and R2, which may be identical or different, designate hydrogen, C1-C6 lower alkyl, straight-chain or branched, or an aryl group, optionally substituted by e...
|
|
WO/1997/014670A1 |
The present invention provides a process for the production of lignan derivatives, which comprises the step of subjecting benzyl substituted succinyl diesters to a Stobbe condensation using lithium methanolate as base in order to produce...
|
|
WO/1997/011937A1 |
A process for producing amide derivatives represented by general formula [XV] or enantiomers thereof, novel intermediate compounds useful for producing these compounds, etc., and a process for producing the same, wherein each symbol is a...
|
|
WO/1997/011938A1 |
A process for producing amide derivatives represented by general formula (XV) or enantiomers thereof, novel intermediate compounds useful for producing these compounds, etc., and a process for producing the same, wherein each symbol is a...
|
|
WO/1997/011071A1 |
A compound of formula (I), wherein R1 and R2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C1-6-alkyl or C1-6-alkoxy; and R3 is hydrogen or C1-3-alkyl; and A is C1-3-alkylene; and Y is >CH-CH2-, >C=CH-, >CH-O-, >C=N-, >N...
|
|
WO/1997/003975A1 |
Fullerene derivatives having formula (I) may be easily produced by a one-pot reaction and are suitable for example for synthesizing new fullerene derivatives and for producing optoelectronic components.
|
|
WO/1997/000869A1 |
A process is provided for the preparation of a variety of triggerable dioxetanes bearing alkoxy, alkenyloxy, alkynyloxy, arlyoxy, aralkyloxy or acyloxy substituents from a common intermediate along with sulfur-substituted dioxetanes and ...
|
|
WO/1996/034846A1 |
Compounds of 1,3-propane diol linked structure (I), when for use in therapy, where R1 is an acyl or fatty alcohol group derived from a C12-30 preferably C16-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hy...
|
|
WO/1996/034855A1 |
Compounds of structure (I), and when for use in therapy: where R1 is an acyl group derived from a C16-30 fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or colu...
|
|
WO/1996/034858A1 |
Niacin as a compound, per se or for use in therapy, of structure (I), where B is -C(=O)- (nicotinic acid) or -CH2-O- (niacin alcohol), the "link" C which is optional is a diol or hydroxy carboxylic acid or dicarboxylic acid residue, and ...
|
|
WO/1996/024849A1 |
1,2-Dioxetane compounds bearing a proteolytic enzyme specific amino acid or peptide are provided, which amino acid or peptide can be removed by action of the corresponding protease. When the amino acid or peptide is removed, the 1,2-diox...
|
|
WO/1996/016137A1 |
A chemiluminescent assay method and compositions are described which use a dialkyl-substituted dioxetane which is deprotected to trigger a chemiluminescent reaction. Chemiluminescent 1,2-dioxetane compounds substituted on the dioxetane r...
|
|
WO/1996/015122A1 |
A chemiluminescent assay method and compositions are described which use a haloalkoxy group-substituted dioxetane which is deprotected by a hydrolytic enzyme to undergo a chemiluminescent reaction. Chemiluminescent 1,2-dioxetane compound...
|
|
WO/1996/004241A2 |
Guanidine derivatives of formula (I) wherein R1 is hydrogen, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, acyl(lower)alkoxy, acyl(lower)alkenyl, or acyl, and R2 is ar(lower)alkenyl; aryl substituted with two suitable substituents;...
|
|
WO/1995/017672A1 |
Chemiluminescent assays for the determination of the presence or amount of a biopolymer in bound assays using 1,2-dioxetanes in connection with AttoPhosTM as chemiluminescent substrates for enzymelabeled targets or probes is provided. Fu...
|
|
WO/1995/000034A1 |
A polyglycerol composition of formula (I), wherein R may be (a), (b), (c) or (d), C comprises up to about 3 percent of all N+M units, and N+M is a number from about 3 to about 15, and wherein the polyglycerol is essentially free of low m...
|
|
WO/1994/026726A1 |
Novel 1,2-dioxetanes with improved chemiluminescent properties, such as signal intensity, S/N ratio, T1/2, etc. are provided by spiroadamantyl 1,2-dioxetanes, wherein the remaining carbon atom of the ring bears an alkoxy, aryloxy, or ary...
|
|
WO/1994/021821A1 |
Chemiluminescent bioassays for the presence or concentration of an analyte in a sample use 1,2-dioxetanes as substrates for the enzyme of an enzyme complex that bind to the analyte. The chemiluminescence obtained from the decomposition o...
|
|
WO/1994/018190A1 |
To provide a compound that promotes the incorporation of LDL from the blood into the liver. A depsidone compound represented by formula (1).
|
|
WO/1994/012175A1 |
The object of the invention is to provide an excellent lipid level depressant. A lipid level depressant containing a penicillide compound represented by general formula (I) as the active ingredient, wherein R represents a group represent...
|
|
WO/1994/010258A1 |
Chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compounds are disclosed in which the aryl group is poly-substituted with suitable electron-donating groups such that the light-emitting pattern of the molecule results in a ve...
|
|
WO/1994/009147A1 |
FO-1289 substance comprising FO-1289A substance, FO-1289B substance, FO-1289C substance and FO-1289D substance, which has inhibitory activity for acylcoenzyme A cholesterol acyltransferase is produced by culturing Aspergillus Sp. FO-1289...
|
|
WO/1994/003271A1 |
A compound of formula (I), in which M is a transition metal ion; A is a counter-ion if required; r, s and t are independently 0 to 3 such that r+s+t is in the range of 1 to 3; Ra, Rb, Rc are each independently hydrogen or CH2OR\' where R...
|
|
WO/1993/013045A1 |
The invention relates to a polymeric optical amplifier doped with lanthanide ions, which are present in the amplifier in the form of a complex. The invention also relates to novel electrically neutral lanthanide complexes which can be ap...
|
|
WO/1993/011122A1 |
Compounds of formula (I) where A is a C1 or C2 alkylene chain optionally substituted by lower alkyl, Z is a bicyclic oxygen-containing radical (e.g. 2,3-dihydro-1,4-benzodioxin-5-yl), R is hydrogen or lower alkyl, R1 is aryl or aryl(lowe...
|
|
WO/1993/010107A1 |
Phenol derivatives are described as agonists of a cyclic AMP dependent protein kinase useful as medicaments.
|
|
WO/1993/008144A1 |
A process for oxidising a substrate susceptible to nucleophilic oxidation by reacting a bicarbonate or monopersulphate solution with the substrate is disclosed. In one aspect the substrate is introduced into the reaction mixture in an in...
|
|
WO/1992/022547A1 |
This invention concerns a cyclic ether of the formula [CF2CFHOR4CF2CH2O]q , wherein R4 is perfluoroalkylene and q is 2, 3 or 4. In preferred cyclic ethers, R4 is -[CF2CF(CF3)O]t(CF2)u-, wherein u is 1 to 10 and t is 1 to 20, and it is es...
|
|
WO/1992/022546A1 |
Stable, optically active enantiomers of substituted glyceraldehydes or glycidaldehydes are synthesized by using osmium-catalyzed asymmetric dihydroxylation of an olefin which is a substituted 1,5-dihydro-3H-2,4-benzodioxepine. For exampl...
|
|
WO/1992/018494A1 |
Oxime ethers of general formula (I), wherein R2 and R3 together with the two carbon atoms to which they are bonded form an unsubstituted or substituted five- to seven-membered ring comprising 1 or 2 oxygen atoms, and R1 and X are as defi...
|
|
WO/1992/015573A1 |
The practicality of known depolymerization reactions in which there is a danger of building up adherent residues on heat transfer surfaces is greatly improved by performing the process under conditions that provide a driving force which ...
|
|
WO/1992/014722A1 |
An improved process for the preparation of cyclic ketene acetals such as 2-methylene-1,3-dioxepane is provided. This process entails reacting at an elevated temperature a halogenated cyclic ketene acetal such as 2-chloromethyl-1,3-dioxep...
|
|
WO/1992/014723A1 |
An improved process for the purification of cyclic ketene acetals such as 2-methylene-1,3-dioxepane is provided. This process entails the purification of the cyclic ketene acetal by distillation in the presence of a solvent and an amine.
|
|
WO/1992/006061A1 |
An iridoide derivative synthesized from genipin, an aglycon of geniposide, which is useful as an antihyperlipemic agent and chologogue.
|
|
WO/1992/004341A1 |
Enzymatically cleavable chemiluminescent 1,2-dioxetane compounds capable of producing light energy when decomposed, substantially stable at room temperature before a bond by which an enzymatically cleavable labile substituent thereof is ...
|
